Cargando…

Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study

INTRODUCTION: The burden of mild-to-moderate atopic dermatitis (AD) in the United Kingdom (UK) is not well understood. Long-lasting AD flares may lead to systemic inflammation resulting in reversible progression from mild to more severe AD. This study aimed to assess the clinical and economic burden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toron, Farah, Neary, Maureen P., Smith, Timothy W., Gruben, David, Romero, William, Cha, Amy, Patel, Keyur, Vasileva, Simona Z., Ameen, Mahreen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163940/ https://www.ncbi.nlm.nih.gov/pubmed/33846907 http://dx.doi.org/10.1007/s13555-021-00519-7

Ejemplares similares

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey
por: Luger, Thomas, et al.
Publicado: (2022)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case–Control Study in Sweden
por: Ortsäter, Gustaf, et al.
Publicado: (2020)

Response to the Letter to the Editor Regarding “Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis”
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis
por: Seghers, Amelie Clementine, et al.
Publicado: (2014)

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
por: de Lucas, Raúl, et al.
Publicado: (2019)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Perception and Experience of Biologic Therapy in Atopic Dermatitis: A Qualitative Focus Group Study of Physicians and Patients in Europe and Canada
por: Ameen, Mahreen, et al.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Psychosocial Comorbidities and Health Status Among Adults with Moderate-to-Severe Atopic Dermatitis: A 2017 US National Health and Wellness Survey Analysis
por: Kwatra, Shawn G., et al.
Publicado: (2021)

The Economic and Psychosocial Comorbidity Burden Among Adults with Moderate-to-Severe Atopic Dermatitis in Europe: Analysis of a Cross-Sectional Survey
por: Girolomoni, Giampiero, et al.
Publicado: (2020)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases
por: Ortsäter, Gustaf, et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

A Real-World Data Study on the Healthcare Resource Use for Uncontrolled Moderate-to-Severe Atopic Dermatitis in Secondary Care in the United Kingdom Prior to the Introduction of Biologic Treatment
por: Hudson, Richard D A, et al.
Publicado: (2022)

Paediatric atopic eczema (atopic dermatitis) in South Africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice
por: Kannenberg, Susanna M., et al.
Publicado: (2020)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Ferrucci, Silvia, et al.
Publicado: (2023)

Tolerability and Efficacy of a Medical Device Repairing Emollient Cream in Children and Adults with Mild to Moderate Atopic Dermatitis
por: Pinter, Andreas, et al.
Publicado: (2019)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Medihoney Derma Cream Treatment for Mild to Moderate Atopic Dermatitis in Children: An Open-Label Randomized Pilot Study
por: Horev, Amir, et al.
Publicado: (2022)

Prediction of disease severity using serum biomarkers in patients with mild-moderate Atopic Dermatitis: A pilot study
por: Lee, In-Seon, et al.
Publicado: (2023)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Correction to: Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Burden of Moderate to Severe Atopic Dermatitis in Adults from France, Italy, and the UK: Patient-Reported Outcomes and Treatment Patterns
por: Kleyn, C. Elise, et al.
Publicado: (2022)

Atopic dermatitis
por: Werfel, Thomas
Publicado: (2011)

Atopic dermatitis
por: Watson, Wade, et al.
Publicado: (2011)

Atopic dermatitis
por: Kapur, Sandeep, et al.
Publicado: (2018)

Atopic dermatitis
por: Galli, Elena, et al.
Publicado: (2020)

Identification of Molecular Signatures in Mild Intrinsic Atopic Dermatitis by Bioinformatics Analysis
por: Yin, Huibin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ocfd2l3ngb0npqm40rah00o6hm